Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy

• Published in: Journal of thrombosis and haemostasis 2017-12, Vol.15 (12), p.2396-2407
• Main Authors: Lee, M. Y., Verni, C. C., Herbig, B. A., Diamond, S. L.
• Format: Article
• Language: English
• Subjects: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology; Adenosine Diphosphate - blood; Adenosine Diphosphate - pharmacology; Blood; Blood Coagulation Disorders - blood; Blood platelets; Blood Platelets - metabolism; Calcium Signaling - drug effects; coagulopathy; Collagen; Collagen - metabolism; Crotalid Venoms - pharmacology; Fibrin; Fibrin - metabolism; Fibrinogen; Glycoprotein VI; GPVI; Humans; In Vitro Techniques; Lectins, C-Type; Metalloproteinase; Microfluidics; Oligopeptides - blood; platelet; Platelet Activation - drug effects; Platelet Membrane Glycoproteins - metabolism; Platelets; Polymerization; Proteinase-activated receptor 1; Signal Transduction - drug effects; Solubility; Thrombin; Thrombin - metabolism; trauma
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.13863

Essentials Collagen and thrombin when used simultaneously generate highly activated platelets. The effect of thrombin stimulation on subsequent glycoprotein VI (GPVI) function was observed. Soluble fibrin, but not protease activated receptor (PAR) activation, prevented GPVI activation. Circulating soluble fibrin in coagulopathic blood may cause an acquired GPVI signaling defect. Summary Background In coagulopathic blood, circulating thrombin may drive platelet dysfunction. Methods/Results Using calcium dye‐loaded platelets, the effect of thrombin exposure and soluble fibrin generation on subsequent platelet GPVI function was investigated. Exposure of apixaban‐treated platelet‐rich plasma (12% PRP) to thrombin (1–10 nm), but not ADP or thromboxane mimetic U46619 exposure, dramatically blocked subsequent GPVI activation by convulxin, collagen‐related peptide or fibrillar collagen. Consistent with soluble fibrin multimerizing and binding GPVI, the onset of convulxin insensitivity required 200–500 s of thrombin exposure, was not mimicked by exposure to PAR‐1/4 activating peptides, was not observed with washed platelets, and was blocked by fibrin polymerization inhibitor (GPRP) or factor XIIIa inhibitor (T101). PAR‐1 signaling through Gαq was not required because vorapaxar blocked thrombin‐induced calcium mobilization but had no effect on the ability of thrombin to impair GPVI‐signaling. Convulxin insensitivity was unaffected by the metalloprotease inhibitor GM6001 or the αIIbβ3 antagonist GR144053, indicating negligible roles for GPVI shedding or αIIbβ3 binding of fibrin. Thrombin treatment of washed platelets resuspended in purified fibrinogen also produced convulxin insensitivity that was prevented by GPRP. Exposure of apixaban/PPACK‐treated whole blood to thrombin‐treated fibrinogen resulted in > 50% decrease in platelet deposition in a collagen microfluidic assay that required soluble fibrin assembly. Conclusions Conversion of only 1% plasma fibrinogen in coagulopathic blood would generate 90 nm soluble fibrin, far exceeding ~1 nmGPVI in blood. Soluble fibrin, rather than thrombin‐induced platelet activation throuh PAR‐1 and PAR‐4, downregulated GPVI‐signaling in response to stimuli, and may lead to subsequent hypofunction of endogenous or transfused platelets.